{"version":"1.0","type":"link","title":"Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).","author_name":"Hodson DJ 외","author_url":"https://prs-insight.online/author/Hodson%20DJ","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/160708","thumbnail_width":1200,"thumbnail_height":630}